Explore Exciting New Career Opportunities at Regeneron

The Armonk campus in Westchester County hosts focused teams in computational biology, data science, and early discovery, leveraging proximity to headquarters for collaborative R&D in AI-driven drug design and genomics analysis.

• Computational Biology: Machine learning models for protein engineering and target identification.
• Data Science and AI: Big data analytics from genetic sequencing.
• Early Discovery Research: Novel target validation in oncology and immunology.
• Bioinformatics: Pipeline development for high-throughput screening.

It enhances Regeneron's innovation through cutting-edge tech integration.

Situated in the Kendall Square biotech hub, the Cambridge campus specializes in gene therapy, RNA therapeutics, and partnerships with academic institutions, advancing next-generation modalities for genetic diseases.

• Gene Therapy: AAV vector design and delivery optimization.
• RNA and Nucleic Acid Therapeutics: siRNA and ASO platforms.
• Platform Technologies: Proprietary delivery systems.
• Collaborative Research: Alliances with MIT and Harvard.
• Early-Stage Oncology: Precision cancer therapies.

It taps into Boston's talent pool for breakthrough innovations.

The Rensselaer campus is Regeneron's key manufacturing and industrial operations site in the Capital Region, specializing in large-scale production of biologics, process development, and supply chain for commercial medicines. It supports advanced bioprocessing technologies for monoclonal antibodies and fusion proteins.

• Biomanufacturing and Process Sciences: Optimizing cell line development, upstream and downstream processes for high-yield production.
• Quality Control and Assurance: Rigorous testing and validation to ensure product safety, efficacy, and regulatory compliance.
• Supply Chain and Logistics: Managing global distribution of therapies like EYLEA and Dupixent.
• Process Engineering: Innovating continuous manufacturing and tech transfer from R&D.
• Analytical Development: Advanced methods for characterization and stability studies.
• Expansion Projects: New facilities for increased capacity in gene therapy and complex biologics.

This campus plays a critical role in scaling Regeneron's discoveries into life-changing treatments, with ongoing expansions to meet growing demand.

The Seattle campus emphasizes immunology and oncology research, leveraging the Pacific Northwest's tech ecosystem for computational and antibody discovery programs.

• Immunology: T-cell engagers and checkpoint inhibitors.
• Oncology: Solid tumor therapies.
• Bioinformatics: Data integration.
• Partnerships: Local tech collaborations.

Expands Regeneron's West Coast presence.

The Sleepy Hollow campus, adjacent to the Tarrytown headquarters, supports specialized research in preclinical development, toxicology, and pathology, contributing to Regeneron's drug discovery pipeline with a focus on safety assessment and translational research.

• Preclinical Safety and Toxicology: Comprehensive non-clinical studies to evaluate drug safety profiles.
• Pathology and Histology: Advanced tissue analysis for disease modeling and efficacy endpoints.
• Bioanalytical Sciences: Biomarker development and pharmacokinetic assessments.
• Comparative Medicine: Animal model research for therapeutic validation.
• Regulatory Affairs Support: Data generation for IND and BLA submissions.

Integrating seamlessly with Westchester operations, it ensures robust safety data for advancing candidates to clinical stages.

The Tarrytown campus serves as Regeneron's corporate headquarters and primary research and development hub, focusing on pioneering biotechnology innovations to treat serious diseases through advanced genetics, antibody engineering, and therapeutic discovery. This main campus houses core scientific teams driving the company's pipeline in immunology, oncology, and rare diseases.

• Genetics and Genomics: Leading the Regeneron Genetics Center, conducting large-scale human genomics research to identify genetic drivers of disease.
• Immunology and Inflammation: Developing monoclonal antibodies for autoimmune disorders and allergic conditions like asthma and atopic dermatitis.
• Oncology: Researching cancer immunotherapies, including bispecific antibodies and combination regimens.
• Neuroscience: Exploring treatments for Alzheimer's, pain, and other neurological disorders using novel modalities.
• Ophthalmology: Innovating therapies for retinal diseases such as diabetic macular edema and wet age-related macular degeneration.
• Rare Diseases and Specialty Medicine: Targeting unmet needs in metabolic, hematologic, and neuromuscular conditions.

With state-of-the-art labs and computational platforms, Tarrytown fosters interdisciplinary collaboration, from early discovery to clinical development, positioning Regeneron at the forefront of precision medicine.

The Warren campus focuses on clinical development, medical affairs, and regional operations, supporting late-stage trials and commercialization in immunology and respiratory diseases.

• Clinical Operations: Phase II/III trial management.
• Medical Affairs: Physician education and KOL engagement.
• Pharmacovigilance: Post-marketing safety monitoring.
• Regional R&D: Specialized immunology research.

It bridges research and market delivery.

The Washington DC office specializes in government affairs, policy, and regulatory strategy, advocating for biotech innovation and patient access to therapies.

• Government Relations: FDA and congressional advocacy.
• Health Policy: Reimbursement and access initiatives.
• Regulatory Affairs: Guidance on approvals.

Key for navigating the policy landscape.